Evaxion A/S (EVAX) Earnings Call Transcript
August 20, 2026
Earnings Call Speaker Segments
Thanks, speaker. This is Helen Tayton-Martin, CEO of Evaxion, and it's a pleasure to be giving our Q2 business update today. With me on this call is Birgitte Rono, our CFO and COO, who'll walk through what's new across our R&D pipeline and our AI Immunology platform. After that, I'll pass things to Thomas Schmidt, who'll take us through the Q2 financial results, and then we'll wrap up with conclusions and Q&A. So, to begin, we may of course be making forward-looking statements, and listeners should review the SEC documents we filed recently. Now let me get the discussion started; Q2 really stands out for a string of accomplishments across the company's 4 core platforms, in our 4 core areas. Starting with business development. As has been the case previously and continues throughout this year, conversations with partners about the action programs and pipeline are ongoing. A steady flow of highly encouraging new data keeps arriving and keeps validating the AI immunology panel, which directly supports those conversations, and some of that we'll get into today; specifically in R&D, we're very pleased to have been accepted to present additional updates on our Evaxion program. our personalized neoantigen cancer vaccine in advanced melanoma patients. And clearly, yesterday was a big day for the whole field, with the positive Phase III — the Phase III results announced from the similar Moderna Merck program in personalized cancer vaccine in melanoma. So it'll be valuable for us and for the field to say more about that, about how we got to ESMO and an update on our own data there. Beyond that, we've been working to refocus and grow the pipeline, taking what we learned with our anti-1 platform into a brand-new program we're calling EVX-05 in glioblastoma, where we're extending the work that let us identify highly conserved antigens for glioblastoma, building on our EVX-04 program and using a comparable approach of applying their immunology to uncover highly conserved and <<inaudible>> in AML. So earlier this year we presented new preclinical data met at the European Hematology Association Conference, Annual Conference. We also gave an update in our infectious disease portfolio on the EVX V1 CMV program at the recent HSV, <<inaudible>> conference last month. On the AI Immunology side more generally—the platform itself—it was genuinely great to see it acknowledged through the Gallian award, which marks the second Gallian honor for this technology within the past 12 months. It's very exciting that this is gaining wider, more global recognition for what AI immunology prediction brings to our programs across infectious disease, oncology, and autoimmune disease. And last, at the heart of our updates: we've kept a disciplined approach to how we allocate resources, tightly aligned with the areas where the platform can deliver the greatest leverage. On that basis, we can confirm our cash runway is unchanged, with funds on hand supporting operations into the second half of 2027, and Thomas will go into more detail on that. So as a quick reminder before we dive in: our pipeline right now comprises multiple programs in cancer and infectious disease. Evaxion will be the subject of a <<inaudible>> presentation shortly, and that naturally includes our EVX-04 and EVX-05 programs, which target the challenges of anti-off-the-shelf antigen vaccines. On the infectious disease side, we have several preclinical programs, some of them partnered—1 with Merck, with Aprogen—and data keeps strengthening the partner interest we're seeing in those programs. So as far as where things stand now that we've reached the midpoint of 2026: we've already hit the first of our milestones, updating on the EVX-01 platform at AACR earlier this year with biomarker immunogenicity preclinical data alongside the year 2 clinical data at ESMO last year. We will—as already mentioned—be providing an update on the 3-year data from that program, with efficacy results, at ESMO in October. Over the remainder of this year, we'll say more about applying AI immunology in autoimmune disease, and about preparing the regulatory filing for that EVX-04 program, the outer-shelf program in AML. And finally, we'll provide an update on our group <<inaudible>> program, covering antigen design and preclinical validation in the EVX-B4. We also continue to pursue a partnership strategy around these programs and platforms wherever we see value creation. With that, I'll pass things to Birgitte, who will walk you through our R&D and AI immunology update.
Thank you, Helen. Today we're putting the spotlight on our lead candidate — the personalized neoantigen cancer vaccine that's presently in Phase II testing for advanced melanoma. After that, I'll introduce our brand-new official EVX-05 vaccine program, which shows how our AI immunology platform scales into glioblastoma, a hard-to-treat and devastating brain cancer. Finally, I'll demonstrate why the T cell epitopes our immunology work uncovers matter for keeping CMV infections under control. As Helen noted, at the ASCO Congress in October we will share 3-year efficacy findings from the Phase II study, and those results cover how the vaccine performs both on its own and together with anti-PD-1 therapy. This information could shed additional light on improved treatment effects as well as how long EBX-01-induced immune responses last. Taken together, these results give a fuller picture of Evaxion's potential, reinforcing a clinical dataset that is already robust. If we look back at data previously disclosed from the Evaxion Phase II trial, we described potent EBX-01-induced immune activation at the AACR meeting in April. We demonstrated that 86% of the EVX-01 vaccine targets set off a tumor-specific immune response — a frequency far above what has been documented for comparable vaccine candidates. On top of that, we showed that 86% of the immunogenic vaccine targets produced a neoantigen response, which means EX1-specific targets generate new responses instead of simply boosting ones that already exist; this matters greatly because triggering novel T cell responses has been tied to clinical benefit. And at last year's ESMO Congress, we presented 2-year outcome data, covering a 75% overall response rate, complete responses, and 92% of the patients remaining in response, which points to durable clinical benefit. Notably, over half of the patients shifted to a better clinical response with their current EVX-01 treatment. Across roughly the last 10 years, personalized neoantigen vaccines have demonstrated promise in multiple early-stage clinical studies. With yesterday's Moderna America announcement, we can confidently state that this field is transitioning from an encouraging experimental immunotherapy into a clinically validated therapeutic modality with a clear and realistic route to regulatory approval. These results aren't merely a win for Moderna and Merck — they're a win for the whole field, since they broadly validate the personalized neoantigen vaccine concept; all in all, given our encouraging EVX-01 data and the validation from Moderna and Merck, we feel we're well positioned as we progress toward credit creation; now let's shift our attention to our off-the-shelf cancer vaccine programs. Working alongside Duke University, we're developing an off-the-shelf vaccine, EVX-05, for glioblastoma, or GBM, that targets conserved antigens, as was announced earlier this week. Okay, so GBM is the primary malignant brain tumor you see most often, and it's also the most aggressive. Even with surgery and then chemoradiation, the results are still very poor — median overall survival is roughly one year, which really points to a major unmet medical need. Our EVX-05 approach is built on the same novel concept as EVX-04, one that can be applied broadly, since it uses AI immunology to go after conserved tumor-specific antigens that come from endogenous retroviruses, or ERVs, which are part of the dark genome. That target selection process lets us cover a wide range of tumors even though immune and tumor antigen differences exist from one patient to another. So we've applied AI immunology. Our AI-driven target discovery went across and pinpointed an optimal set of bar fragments according to trust patient relevance and immunogenic percentage. We also mined patient sequencing data, found roughly 1.5 million <<inaudible>>, and chose 16 of them as the fragments to be put into the EVX-05 vaccine. So the next steps are lead candidate selection and IND enabling activities ahead of a first in-human study, which is expected to be run in collaboration with the world-leading GM experts — we're collaborating with GC University. Now, our other after-shelf cancer vaccine program, EVX-04, is also moving along well. EVX-01 targets in multiple concerts in the case of this program identified in AML patient samples. As Sean mentioned, we presented novel data at the European Hematology Associates Conference in June showing that the EVX-04 vaccine is expressed and secreted by human cells, which enables immune recognition and activation. What's more, we showed that the 16 <<inaudible>> targets included in EVX-04 activate human immune cells across different HLA types, and that these immune cells can mediate targeted cell cooling — indicating not only immune recognition but also a relevant functional impact from these vaccine-induced immune cells. Taken together, these data highlight EBX 4's potential as a new effective therapeutic cancer vaccine, and we look forward to reporting further data as the program moves toward regulatory buying later this year. Another promising program presented at a scientific conference during the summer is our EVX-D1 cytomegaly or CMV vaccine program. In EVX-D1, we're using AI immunology to design a known target — optimizing them — and also to identify previously unexplored vaccine tires. At the international Herpesvirus workshop in July, we presented new data showing that <<inaudible>> discovered with AI immunology have the potential to control acute infection, latency, and also reactivating reactivation in CMV-infected mice. That's a key finding, because it complements earlier results showing the ability of both novel and optimized non-B cell antigens to reduce viral infection. And the data will guide antigen selection for a broadly protective CMV vaccine candid and, as such, represent a very important step toward the EVX-D1 program. So having highlighted progress across our key R&D programs, let's now focus on our AI Immunology platform and the data validating its ability to generate high-quality product candidates. Thus, AI immunology has been clinically validated, showing positive results in 3 out of 3 oncology trials. In preclinical work, we showed vaccine proof of concept spanning various disease areas, such as cancer, using our art-targeting vaccines, plus in taxis diseases with multiple candidates directed at bacterial and viral pathogens. Also important, the EVX-01 concept scales very well with Presento in other solid tumors. Furthermore, the novel air-based cancer vaccine concept gets used in both of our off-the-shelf programs, EVX-04 and EVX-05. So in the end, AI analogy backs multiple modalities—peptides, recombinant proteins, DNA and RNA platforms—allowing both pipeline and powering percent. To sum up, we have shown robust advancement throughout our R&D pipeline, and we anticipate giving updates as our programs move forward. With that, I will pass things to Thomas, who will share our quarterly financial results.
Thank you, Birgitte. I'll move right into walking through the financial results for Q2 2026. Beginning with the key points for this quarter: we've kept up our disciplined approach to allocating resources in line with where our strategy is headed, and that's very much in step with the priorities tied to the value drivers we laid out and shared earlier in the year. So we're fully aligned and fully on track with those items. We're also on course to deliver in line with our financial plan, which comes through in the Q2 numbers and is further supported by the cash position we hold. On that cash position, we can confirm once more, as Helen already noted, that our runway extends into the second half of 2027. So that's reconfirmed and unchanged from what we communicated before. Taking a closer look at the P&L for the quarter: on the whole, operating expenses came down slightly, largely because of our general and administration costs, or G&A, where capital market costs in Q2 were significantly lower than the same period a year ago; on the R&D side, expenses rose a bit compared with last year, but that's entirely matched by all the progress Birgitte just described on EVX-01, EVX-04, and EVX-05, and those programs, again, are confirmed to sit within our cash runway through the half year of 2027; we posted a net loss of $3.7 million for the period, which, as already mentioned, is on plan and follows the execution we set for this year. Turning to the balance sheet, our cash position at quarter-end stands at $14 million; we are, again, reconfirming our cash runway, and the equity we hold mirrors the result for the first 6 months, which puts us at $9.5 million at the close of the second quarter, reflecting that against last year's net result. So overall, a solid financial performance in line with expectations and certainly in line with the progress across our platform and portfolio. With that, I'll hand things back to Helen for some closing remarks.
Appreciate it, Thomas, and thank you as well, Birgitte. To wrap things up, I'd like to highlight that we've demonstrated solid operational progress across our asset milestones, and in fact a new program has come out of all our efforts with EVX-05, while we still keep our cash runway extending into the second half of 2027. The continuous flow of fresh data we've been producing alongside the team has us genuinely enthusiastic, since it keeps confirming that AI immunology is capable of yielding meaningful products for future development. That idea sits at the heart of every business development conversation we're having, as we keep working through which programs to advance and which partners to advance them with. So with that, we're glad to open the floor for questions, and we appreciate your time.
I have just 2 questions regarding EVX-05. I'm wondering whether you might be able to give us a sense of when additional updates from that program could be expected. And after that, could you say a bit more about exactly what role Duke has had in the work done so far?
Of course. So the partnership with <<inaudible>> has been in place for a good while now. They possess a substantial amount of sequencing data from the patients being treated at their clinics. Therefore, we think sequencing data exists for a number of those individuals, and we were able to identify. Initially, we took our presliced approach and examined the profiles of the EV and new antigen expression. And then, as EXO, we are simultaneously moving forward with this off-the-shelf concept that we're developing. We could apply several of those same methods and examine these samples to find conservatives, and it was very encouraging to observe that among these numerous patients, certain features appeared showing we could certainly produce an off-the-shelf or the signing of the shelf therapy. As I said, it remains somewhat early along the development path. We have carried out and completed what we'll refer to as target discovery, meaning choosing the targets to be placed in the vaccine, and at present we are moving toward lead selection — we have created a number of distinct candidates that are currently undergoing experimental testing; and after that comes the standard phase involving R&D-enabling activities, followed by the first in human study. We haven't fully finalized a schedule for all of those activities, but that is what we're focused on right now. So there will definitely be more to come.
I have several questions, but hopefully I can ask them one by one. Let's begin with EVX-01. Clearly, it was thrilling to hear yesterday's announcement regarding the Modena collaboration, since it confirms the value of the program you've been developing for some time now. So as we head into ESMO for the 3-year EVX-01 extension data, Birgitte, what would you view as a clinically meaningful durability result, particularly during the stand-alone vaccine period, and how would that assist your conversations with either the partners currently evaluating this program or even the AI model that helped create EVX-01 more broadly?
Yes. So regarding the EVX-01 clinical data we hope to see at ESMO, essentially it's that we have nearly the same or perhaps even better overall response rate. We need to keep in mind that these patients, those with advanced melanoma, if they get only checkpoint inhibitors, then close to half of them by the 5-year point actually have severe disease or even, yes, die. So there is certainly a significant unmet medical need for these patients. So we want to see durable responses. So the same number of patients stay in response at the 2-year point and additionally that the T cell responses are sustained. So that is — we would regard that as positive data, a positive outcome from this extension base. And then you made another comment about how this data might potentially support a partner positive questions. Yes. So there's no question that the more data, positive data we can produce would be welcomed by — in these discussions. And I think the validation that emerged yesterday for the personalized cancer vaccine concept definitely also is supportive in — or supports us in these discussions. And we have been waiting the wholesale has been waiting for these Phase III data for a long time. And it's not merely a win for the Modena and Merck, but it's actually a win for the entire field. So definitely, we view this as very encouraging and positive and not just — yes, bad competitor is it's very positive.
All right. So moving to EVX-04, the off-the-shelf molecule — when it comes to preparing that for the clinic, which steps are the gating ones? Is manufacturing the issue? Is it CMC, or is it making certain there are sufficient investigators who'd act appropriately once you begin clinical testing?
Right. For EVX-04, target discovery has been completed; the <<inaudible>> has been chosen, and at this point IND-enabling work is underway, which covers GMP manufacturing. Beyond that, naturally, we must verify that the resulting molecule can also trigger a robust immune response. Simultaneously, we're in discussions with clinical sites, making sure a framework exists for testing the EVX-04 molecule. Our intention is to advance this program into the clinic, though we remain, naturally, always keen and are talking with companies; so yes, yes, but whether we form a partnership isn't strictly a prerequisite...
Every one of those efforts is moving forward and proceeding as planned. So when it comes to the clinical sites, the work on the protocol, manufacturing under GMP, and putting together the regulatory paperwork that's required — all of that feeds into the timeline we've shared publicly. So right now there's nothing different and nothing worrying us. We're aware that each of those efforts is on schedule, matching the timelines we've communicated for submitting regulatory filings before this year ends.
We have time for a few additional questions. This one is for Helen. You and even the prior leadership team have spent roughly 2 quarters discussing possible partnerships. So right now, what are you able to share regarding where those talks stand, and could you describe how far along the furthest ones have gotten? What stage are they in? Are they at the due diligence stage, still exploratory, or are you basically in the hands of the <<inaudible>> waiting for them to put things in writing?
Certainly — that is an understandable and fair question, though I am not able to respond with the level of openness you might prefer. In our oncology discussions, clearly the clinical data we hold that has started to be discussed, especially EVX-01, has carried a lot of weight. Still, to a degree, the validation of the entire field — having seen a company with a comparable kind of program manage to move that ahead into a registrational study — has a significant effect. So although we have been engaged in differing levels of dialogue and diligence, the situation has been somewhat one of waiting to see how the field develops. That is why Birgitte's earlier remarks about the positive endorsement this offers matter for all of us who have programs that are genuinely differentiated in what they can deliver, and in indications beyond melanoma too. Within all of that, the novelty surrounding the IRF platform, the capacity to identify conserved antigens from the dark genome, has drawn quite a lot of interest as well. Arriving with the second program there in a brain cancer that is extremely hard to treat speeds up that interest. I have worked in BD for more than 20 years, and when there is motivation and competition, things can move very quickly, while at other times it can take 2 years. So I would say we are having active conversations, and we will obviously be glad to provide an update when we are able to.
Alright, just one more from my side. Thomas, looking at how things went in the first half, roughly $80 million of cash was used, and it seems like you're burning around $4 million or more each quarter. Given the $14 million sitting in the bank right now, could you take us through what you're assuming for reaching the second half of '27? And do you anticipate any cash coming in, whether through organic means or otherwise?
Yeah. No, that's fine. Appreciate it, RK. Let me start with the first piece of what you asked. The way our cash goes out isn't linear — you can't simply take each quarter and extrapolate from that. Obviously, what happened and what we did in Q2, and even Q1, can't just be carried straight through for the entire year. There are variations. At this point, we are at, and anticipate staying at, the level we previously communicated — approximately $14 million — and I'd actually anticipate it coming in a bit under that. So it isn't a precise round number as such; naturally, we do have that $14 million, as you correctly noticed, sitting in the bank account. Also keep in mind, naturally, that certain normal swings occur because we're mainly a DKK-based company as opposed to U.S. So there are some movements from a purely ForEx standpoint affecting that as well. Beyond that — we continue to believe that, with the runway we have and with our discipline around where and how we allocate spending, we can still, as stated before, affirm that we'll reach the second half of 2027. And naturally, we'll take advantage of the various options at our disposal. One of them is also — not that it's been factored in, I should note, into how we laid out reaching half 2 '27, but an ATM facility is something we can draw on. And in fact, only yesterday, we began activating a portion of that ASM in the market as well. So, driven naturally by the positive news we've observed along with the volume in our price. We'll leverage those kinds of opportunities from an ATM standpoint, and beyond that, whenever we eventually announce deals or partnerships, that will surely contribute as well; but with the straight runway we currently have and our prioritized programs, we're quite confident we'll make it into the second half of 2027.
On this call for Debanjana, we also had a handful of questions. The first thing we wanted to ask: among glioblastoma patients, which ones stand the best chance of gaining benefit from the EVX-05 cancer vaccine your company is working on?
Please name the particular group. We're continuing our efforts to pin down patient subsets, examining the various ERV profiles to figure out which population would be optimal. Beyond that, we're naturally investigating standard of care along with combination therapies — one path is to exercise some caution about pairing a vaccine with chemotherapy, or instead focusing on those patients who aren't getting results from chemotherapy treatments; however, we haven't fully landed on the details regarding the clinical <<inaudible>>.
Okay. Then, just to tack on a quick second question: what kind of timeline ought we to anticipate for getting that initial first-in-human clinical trial underway, and which important milestones should investors keep an eye out for prior to that study starting?
Yes. Well, we remain at an early stage of preclinical development. Our target discovery work has been wrapped up. So we're applying our AI immunology to mine the patient data, and at this point we have an optimal set that will go into the EVX-05 vaccine. So screening is underway, we've designed a number of distinct vaccine candidates, and are right now experimentally evaluating those in order to pick the lead candidates. After that come the standard activities, the activities that happen ahead of the first-in-human study. And as I said, we're collaborating with Duke University. No firm time lines have been shared by us for this program, because we need — we need to see, above all, the selection before we begin communicating time lines.
When it comes to how we deliver the EVX-04 platform, we will certainly draw on the know-how and background we've built there for certain aspects of GMP manufacturing. So expect further details on timing, though of course we already understand a great deal about advancing a platform of this type, because of the approach we've previously taken with EVX-04.
Then, as a closing question: past glioblastoma, how wide do you think the ERB targeting strategy can reach across different solid tumors? And more generally, how does EVX-05 slot into the longer-term plan of creating that AI-driven oncology franchise?
Yeah. We've done quite a bit of work employing immunology to mine patient data across the various indications, and we are seeing that particular patient types carry bad antigens. So applying this approach more widely is certainly an option, though it hinges on the profiles of those indications. Still, there are certainly more possibilities for expanding this into additional solid tumors as well as hematologic ones.
And I think what's intriguing is that frequently, in cases where mutational burden isn't high, there's usually still a high frequency, and that's exactly what we've been examining. So frequently, when there's no chance to move ahead with a personalized strategy because mutational burden is low, that appears not to hold true for the ERFs—more details to follow on that as we've been working through this piece. So we believe it genuinely widens the opportunity regarding what we—the counter vaccine can achieve for novel targets.
Thanks — and I appreciate all of you joining us today, plus the great questions we received; we're genuinely thrilled about the operational momentum we've managed to produce, though the curiosity around the programs is arriving against what is a truly thrilling period for personalized cancer vaccines across the entire field; so there are exciting developments ahead, and we look forward to bringing you more updates during the second half of the year. Thank you.
Appreciate it. That brings us to the end of the call for today. Thanks for joining in. You're welcome to hang up at this point.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete Evaxion A/S transcript - plus 132,000+ transcripts from 7,000+ companies, speaker segments and full-text search - through the EarningsAPI REST API or hosted MCP server.
Get an API key View API docs →For developers and AI pipelines
Programmatic access to Evaxion A/S earnings transcripts and 132,000+ others is available through the
EarningsAPI REST API and the hosted MCP server.
Quarterly plans from $162 - full transcripts, speaker segments, full-text search,
and the /api/v1/transcripts/recent polling endpoint for ETL pipelines.